Metsera (NASDAQ:MTSR) Stock Price Up 7.4% – Time to Buy?

Metsera, Inc. (NASDAQ:MTSR) rose 7.4% on Tuesday . The stock traded as high as $20.00 and last traded at $19.53. Approximately 178,578 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 780,994 shares. The stock had previously closed at $18.18.

Wall Street Analyst Weigh In

A number of brokerages have commented on MTSR. Evercore ISI began coverage on Metsera in a report on Tuesday, February 25th. They set an “outperform” rating for the company. Cantor Fitzgerald assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating for the company. Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target for the company. Finally, Guggenheim assumed coverage on Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price on the stock.

Metsera Stock Down 8.4 %

The company has a 50 day simple moving average of $25.58.

Metsera (NASDAQ:MTSR) last announced its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.